BioCardia CEO Peter Altman buys 500 common shares

Both reported per-share prices are weighted averages, and the footnotes give separate execution ranges for each day's trades.

Rhea-AI Filing Summary

BioCardia, Inc. (BCDA) President and CEO Peter Altman, a director, reported direct purchases totaling 500 shares of common stock. He purchased 200 shares on October 15, 2026, and 300 shares on October 16, 2026, each at a reported weighted-average price of $0.95 per share. Footnotes give trade ranges of $0.94–$0.95 for October 15 and $0.94–$0.96 for October 16. The Rule 10b5-1 plan box was unchecked.

Insider Trade Summary

Net Buyer: 500 shares

Net Buy 2 txns

Insider Altman Peter

Role President and CEO

Bought 500 shs ($475.00)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2	300	$0.95	$285.00
Purchase	Common Stock F1	200	$0.95	$190.00

Holdings After Transaction: Common Stock — 385,385 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades ranging from $0.94 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
2. F2. This transaction was executed in multiple trades ranging from $0.94 to $0.96 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Total shares purchased: 500 shares Shares purchased: 200 shares Weighted-average price: $0.95 per share +2 more

5 metrics

Total shares purchased 500 shares Direct common stock purchases reported on October 15 and October 16, 2026

Shares purchased 200 shares Direct purchase on October 15, 2026

Weighted-average price $0.95 per share October 15, 2026 purchase; trades ranged from $0.94 to $0.95 per share

Shares purchased 300 shares Direct purchase on October 16, 2026

Weighted-average price $0.95 per share October 16, 2026 purchase; trades ranged from $0.94 to $0.96 per share

Key Terms

weighted average per share sales price, Rule 10b5-1 plan, open market or private transaction

3 terms

weighted average per share sales price financial

"price reported above reflects the weighted average per share sales price"

Rule 10b5-1 plan regulatory

"Rule 10b5-1 plan box was unchecked"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BCDA shares did Peter Altman buy, and at what price?

Peter Altman, BioCardia's President and CEO and a director, reported direct purchases of 500 common shares: 200 shares on October 15, 2026, and 300 on October 16. Each was reported at $0.95 per share as a weighted average; the respective trade ranges were $0.94–$0.95 and $0.94–$0.96. The Rule 10b5-1 plan box was unchecked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 05:42 PM EDT Accepted by SEC EDGAR 10/20/2026 - 05:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2026		P		200(1)	A	$0.95(1)	385,085	D
Common Stock	10/16/2026		P		300(2)	A	$0.95(2)	385,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.94 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $0.94 to $0.96 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ Peter Altman	10/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)